top of page

GPCR News Powered by our Strategic Partners

Post: Blog2_Post
Search

Allosteric Binding Demystified: Smarter GPCR Drug Discovery

Molecular graphics with the text "Beyond Potency: The Kinetic Key to Unlocking In Vivo Efficacy" on white background, featuring scientific designs.
In the realm of molecular research, precise interpretation is crucial; a misread curve can lead to lost compounds.

Hello GPCR Enthusiasts,


Interpreting binding data isn’t optional—it’s career-defining. When assays behave unpredictably, the wrong interpretation doesn’t just waste time; it costs viable compounds, credibility, and millions in development risk.



Breakthroughs this week: Decoding ADGRE5 signaling; Eli Lilly’s obesity pill vs Novo’s Wegovy; Certa Therapeutics patents GPR68 antagonists.



🔍 This Week in Dr. GPCR Premium: Sneak Peek


Every week, Premium Members get curated intelligence they won’t find in open channels. Here’s a preview of what’s inside this week’s Premium Edition:


  • Industry insights: Metabolic GPCRs in the spotlight; receptor motion tracking tools; obesity treatment race between Eli Lilly and Novo

  • Upcoming events: September GPCR symposia across Europe, UK, and online—including neuroGPCR signaling deep-dives.

  • Career opportunities: Postdocs in GPCR biophysics and assay development; industry scientist roles at BPS Bioscience.

  • Must-read publications: Tryptophan-cholic acid and MRGPRE in glucose homeostasis; Biased signaling in short- vs long-acting β2-agonists.





Terry's Corner - The Truth About Allosteric Displacement



Allosteric binding isn’t just a twist in the pharmacology playbook—it rewrites the rules entirely.


This week, Dr. Terry Kenakin exposes why traditional displacement logic breaks down in allosteric systems, and how overlooking this can derail entire programs.


  • Protect your pipeline: Misinterpreting displacement curves in allosteric assays means discarding viable compounds—or worse, advancing misleading ones.

  • Gain competitive clarity: Learn how binding and function diverge, and why that divergence is the key to harnessing allostery, not fearing it.

  • Avoid costly blind spots: Discover how G protein stoichiometry can dictate whether your assay informs—or deceives.



💡 Premium Members also receive a 50%+ discount when they join Terry’s Corner.






Yamina’s Corner - The Hidden Cost of Busy



A GPCR program can collapse—not because of bad science, but because brilliant teams are forced into duct tape systems.


Yamina’s Corner reveals how fragmented data, undefined workflows, and ambiguous decision gates silently bleed six figures from every DMTA cycle.


  • Eliminate chaos tax: Every two-week delay in DMTA cycles costs hundreds of thousands—avoidable with precision systems.

  • Stop wasting talent: When senior leaders spend nights copy-pasting data, your burn rate accelerates while innovation stalls.

  • Blueprint for survival: Continuous improvement and operational scaffolding—not more hires—are the real drivers of resilience.





Discovery on Target - The Next Wave of GPCR Drug Discovery


The 20th Annual GPCR-Based Drug Discovery Conference isn’t just another event—it’s where the frameworks shaping the next decade are revealed. From biased ligands to computational targeting, this is where the pipelines of the 2030s begin.


  • Featured Talk: Dr. Terry Kenakin on The Kinetics of Allostery.

  • Exclusive Discount: Use code DRGPCR25 for $200 off.






Why Dr. GPCR Premium Membership Gives You an Edge



The GPCR field is advancing at breakneck speed. Premium delivers clarity where noise dominates. Each week, you gain curated intelligence across science, careers, and strategy:


  • Deep-dive expert lectures and frameworks.

  • Classified industry updates and event alerts.

  • Tailored job opportunities and career matchmaking.

  • Exclusive discounts and member-only access to resources.



With Premium, you move faster, smarter, and more confidently than peers relying on scattered signals.



FAQ: Premium Membership



🔹 What’s included?

The complete Weekly News digest, curated jobs, upcoming events, classified GPCR publications, exclusive on-demand expert lectures, and member-only discounts.


🔹 Who is it for?

GPCR scientists, translational pharmacologists, biotech discovery teams, and decision-makers who need career-relevant intelligence to stay ahead.


🔹 Why now?

The pace of GPCR innovation is accelerating. Those who act on the right signals today will lead tomorrow’s breakthroughs—and avoid delays others won’t see coming.


👉 Don’t Fall Behind—Access the Edge You Need

👉 Already a Premium Member? Read the Premium edition here ➤




What our members say


🗣️ "Dr. Kenakin is a leading expert in the field. Aside from his vast experience in drug development, not to mention his extensive publication record, Dr. Kenakin is a masterful teacher and communicator." — DrGPCR University Attendee

The difference between stalled programs and breakthrough therapies often lies in a single insight delivered at the right time. Premium Membership ensures you never miss it.



Comments

bottom of page